ProJenX Alternatives & Competitors
12 companies similar to ProJenX — ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhi...
NeuroSense Therapeutics
Creatively and diligently moving fast towards an effective treatment for people with ALS.
Cambridge, United States
Adamant Health
Revolutionizing the care of Parkinson’s disease.
Kuopio, Finland
Dunad Therapeutics
Tunable covalent chemistry with a deep understanding of disease biology to develop transfo...
Cambridge, United States
Novoron Bioscience
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the...
San Diego, United States
Track all ProJenX competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
Mclean, United States
ROME Therapeutics
Harnessing the power of the repeatome to develop a new class of therapies for cancer and a...
Boston, United States
Aspen Neuroscience, Inc.
Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and...
La Jolla, United States
Evox Therapeutics Ltd
Changing the course of CNS disease
Oxford, United Kingdom
Vertero Therapeutics, Inc.
Pioneering science beyond the brain to treat neurodegenerative diseases at their source
Woburn, United States
HepaTx Corporation
Off-the-shelf cell therapies for liver disease
Palo Alto, United States
BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift...
Cambridge, United States
Point Pressure
Developing the next big leap in spasticity treatments.
Sant Cugat Del Valles, Sp...
About ProJenX
ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for ALS & other diseases.
Drug Development for ALS, Clinical Trial Execution, Research and Development of Neurodegenerative Therapies, Discovery and Preclinical Testing of Kinase Inhibitors
Individuals with Amyotrophic Lateral Sclerosis (ALS), Healthcare Providers in Neurology, Research Institutions Focusing on Neuroscience, Neurodegenerative Disease Community
Clinical-stage Biotechnology, Neurodegenerative Diseases, ALS Therapy, Brain-penetrant Therapies, MAPK Therapeutics, Motor Neuron Degenerative Pathways, Small Molecule Therapeutics, Patient-specific Discovery Platform, Neuroscience Medicines, Prosetin Development, Research Collaboration, Biopharmaceutical Innovation, Neurology
B2B, B2D
Licensing, Performance Based, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches ProJenX and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at ProJenX on 9 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
